| HOME >> MEDICINE >> TECHNOLOGY |
Advantages and Alternatives II-26
Table 2: World Lovenox Sales by Geographic Region
(2009-2011): Breakdown of Value Sales in US$ Million for
Western Europe, US, Emerging Markets and Others (includes
corresponding Graph/Chart) II-27
Fragmin (dalteparin sodium) II-27
Approved Indications for Fragmin Use II-28
Contraindications II-28
Precautions II-29
Fraxiparine (nadroparin) II-29
Innohep (tinzaparin) II-29
Contraindications II-30
Side Effects II-30
Other Serious Adverse Events Associated with Innohep II-31
Precautions II-31
Normiflo (ardeparin) II-31
Clivarine (reviparin) II-32
Table 3: Summary of Available LMWHs II-32
A Comparison of FDA Approved Indications for Select Injectable
LMWHs - Lovenox, Innohep and Fragmin II-33
Non-Heparin Anticoagulant Injectables - An Overview II-33
Arixtra (fondaparinux) II-33
Contraindications II-34
Market and Market Participants II-34
Angiomax (bivalirudin) II-34
Advantages II-35
Contraindications II-35
Side Effects II-35
Argatroban/Novastan II-35
Side Effects II-36
Precautions II-36
Refludan (lepirudin) II-36
Orgaran (danaparoid Sodium) II-37
Contraindications II-37
Side Effects II-38
Caution II-38
Precaution II-38
A Comparative Analysis of Various Direct Thrombin Inhibitors II-38
5. A COMPARATIVE STUDY OF ANTICOAGULANT THERAPIES II-39
A Comparative Study of Warfarin Against LMWHs II-39
A Comparative Study of LMWH Against UFH II-40
A Comparative Study of New Anticoagulants/ Anticoagulant
Candidates Against Warfarin II-41
A Comparative Study of Heparin Against Angiomax II-41
A Comparative Study of Arixtra Against UFH and LMWH II-41
A Comparative Study of Angiomax Against UFH and LMWH II-4
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |